THROMBOELASTOGRAPHY MARKET ANALYSIS

Regional Analysis

Global Thromboelastography Market– Regional Analysis

On the basis of region, the global thromboelastography market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to hold a dominant position in the market during the forecast period, owing to the increasing number of approvals by regulatory authorities is expected to drive the market growth over the forecast period. For instance, Idarucizumab, a monoclonal antibody specific for the dabigatran molecule, has now received the U.S. FDA approval for use as an antidote. Similar antibodies are being developed to ask the FDA for permission to reverse xabans (Xa) inhibitors like Andexanet Alpha. Since the thrombin time and the ecarin clotting time, which can quantify coagulation with the Non-Vitamin K antagonist oral anticoagulants (NOACs), are not widely available, it is likely that the Thromboelastography (TEG)/ Thromboelastometry (ROTEM) will be used to determine the efficacy of these antidotes.

Figure 2: Global Thromboelastography Market Value (US$ Mn), by Region, 2022

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa